Low-grade neuroepithelial tumor

Unusual presentation in an adult without history of seizures

Giulio Riva, Luca Cima, Manuela Villanova, Claudio Ghimenton, Sokol Sina, Luca Riccioni, Giada Munari, Matteo Fassan, Felice Giangaspero, Albino Eccher

Research output: Contribution to journalArticle

Abstract

Low-grade neuroepithelial tumors (LGNT) show a broad histopathological spectrum and may be difficult to classify using current World Health Organization (WHO) criteria. A 57-year-old man came to medical attention because of headaches. The patient medical history was otherwise unremarkable. Magnetic resonance imaging (MRI) revealed a 2.5 cm lesion, partially cystic, with an increased signal on T2-weighted imaging, located in the right frontal lobe. The patient underwent right frontal craniotomy and the surgical specimen was entirely evaluated. Microscopic examination showed a tumor arranged predominantly in sheets and nests, with an infiltrative growth pattern and oligodendroglioma-like appearance. Tumor cells were round to oval with cytoplasmic clearing, hyperchromatic nuclei and inconspicuous nucleoli. Only one mitosis was identified. Necrosis was absent. Differential diagnostic considerations included oligodendroglioma, clear cell ependymoma, polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and long-term epilepsy-associated tumor with clear cell morphology. Neoplastic cells showed positivity for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), α-thalasemia X-linked mental retardation syndrome (ATRX) (retained nuclear expression) and CD34. Epithelial membrane antigen (EMA), neuronal nuclear antigen, microtubule-associated protein-2e, cyclo-oxygenase-2, chromogranin A and isocitrate dehydrogenase 1 (IDH1) (R132H) were negative. Ki-67 labeling index was 2–3%. Molecular analysis identified neither IDH1/IDH2 mutations nor 1p19q codeletion. Rapidly accelerated fibrosarcoma homolog B1 (BRAF) V600E mutation was also absent by both molecular and immunohistochemical testing. Polymerase chain reaction analysis revealed the presence of fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil (TACC) fusion. Taken together, the morphological, immunohistochemical and molecular findings supported the final diagnosis of PLNTY.

Original languageEnglish
Pages (from-to)557-560
Number of pages4
JournalNeuropathology
Volume38
Issue number5
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Neuroepithelial Neoplasms
Oligodendroglioma
Isocitrate Dehydrogenase
Seizures
Receptor, Fibroblast Growth Factor, Type 3
X-Linked Mental Retardation
Ependymoma
Chromogranin A
Mucin-1
Neoplasms
Nuclear Antigens
Mutation
Microtubule-Associated Proteins
Fibrosarcoma
Craniotomy
Glial Fibrillary Acidic Protein
Oligodendroglia
Patient Rights
Frontal Lobe
Prostaglandin-Endoperoxide Synthases

Keywords

  • brain tumors
  • CD34
  • FGFR3-TACC3 fusion
  • low-grade neuroepithelial tumor
  • PLNTY

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Neurology

Cite this

Riva, G., Cima, L., Villanova, M., Ghimenton, C., Sina, S., Riccioni, L., ... Eccher, A. (2018). Low-grade neuroepithelial tumor: Unusual presentation in an adult without history of seizures. Neuropathology, 38(5), 557-560. https://doi.org/10.1111/neup.12504

Low-grade neuroepithelial tumor : Unusual presentation in an adult without history of seizures. / Riva, Giulio; Cima, Luca; Villanova, Manuela; Ghimenton, Claudio; Sina, Sokol; Riccioni, Luca; Munari, Giada; Fassan, Matteo; Giangaspero, Felice; Eccher, Albino.

In: Neuropathology, Vol. 38, No. 5, 01.10.2018, p. 557-560.

Research output: Contribution to journalArticle

Riva, G, Cima, L, Villanova, M, Ghimenton, C, Sina, S, Riccioni, L, Munari, G, Fassan, M, Giangaspero, F & Eccher, A 2018, 'Low-grade neuroepithelial tumor: Unusual presentation in an adult without history of seizures', Neuropathology, vol. 38, no. 5, pp. 557-560. https://doi.org/10.1111/neup.12504
Riva G, Cima L, Villanova M, Ghimenton C, Sina S, Riccioni L et al. Low-grade neuroepithelial tumor: Unusual presentation in an adult without history of seizures. Neuropathology. 2018 Oct 1;38(5):557-560. https://doi.org/10.1111/neup.12504
Riva, Giulio ; Cima, Luca ; Villanova, Manuela ; Ghimenton, Claudio ; Sina, Sokol ; Riccioni, Luca ; Munari, Giada ; Fassan, Matteo ; Giangaspero, Felice ; Eccher, Albino. / Low-grade neuroepithelial tumor : Unusual presentation in an adult without history of seizures. In: Neuropathology. 2018 ; Vol. 38, No. 5. pp. 557-560.
@article{928df1d23a9040d6ad6f5addee6057a3,
title = "Low-grade neuroepithelial tumor: Unusual presentation in an adult without history of seizures",
abstract = "Low-grade neuroepithelial tumors (LGNT) show a broad histopathological spectrum and may be difficult to classify using current World Health Organization (WHO) criteria. A 57-year-old man came to medical attention because of headaches. The patient medical history was otherwise unremarkable. Magnetic resonance imaging (MRI) revealed a 2.5 cm lesion, partially cystic, with an increased signal on T2-weighted imaging, located in the right frontal lobe. The patient underwent right frontal craniotomy and the surgical specimen was entirely evaluated. Microscopic examination showed a tumor arranged predominantly in sheets and nests, with an infiltrative growth pattern and oligodendroglioma-like appearance. Tumor cells were round to oval with cytoplasmic clearing, hyperchromatic nuclei and inconspicuous nucleoli. Only one mitosis was identified. Necrosis was absent. Differential diagnostic considerations included oligodendroglioma, clear cell ependymoma, polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and long-term epilepsy-associated tumor with clear cell morphology. Neoplastic cells showed positivity for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), α-thalasemia X-linked mental retardation syndrome (ATRX) (retained nuclear expression) and CD34. Epithelial membrane antigen (EMA), neuronal nuclear antigen, microtubule-associated protein-2e, cyclo-oxygenase-2, chromogranin A and isocitrate dehydrogenase 1 (IDH1) (R132H) were negative. Ki-67 labeling index was 2–3{\%}. Molecular analysis identified neither IDH1/IDH2 mutations nor 1p19q codeletion. Rapidly accelerated fibrosarcoma homolog B1 (BRAF) V600E mutation was also absent by both molecular and immunohistochemical testing. Polymerase chain reaction analysis revealed the presence of fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil (TACC) fusion. Taken together, the morphological, immunohistochemical and molecular findings supported the final diagnosis of PLNTY.",
keywords = "brain tumors, CD34, FGFR3-TACC3 fusion, low-grade neuroepithelial tumor, PLNTY",
author = "Giulio Riva and Luca Cima and Manuela Villanova and Claudio Ghimenton and Sokol Sina and Luca Riccioni and Giada Munari and Matteo Fassan and Felice Giangaspero and Albino Eccher",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/neup.12504",
language = "English",
volume = "38",
pages = "557--560",
journal = "Neuropathology",
issn = "0919-6544",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Low-grade neuroepithelial tumor

T2 - Unusual presentation in an adult without history of seizures

AU - Riva, Giulio

AU - Cima, Luca

AU - Villanova, Manuela

AU - Ghimenton, Claudio

AU - Sina, Sokol

AU - Riccioni, Luca

AU - Munari, Giada

AU - Fassan, Matteo

AU - Giangaspero, Felice

AU - Eccher, Albino

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Low-grade neuroepithelial tumors (LGNT) show a broad histopathological spectrum and may be difficult to classify using current World Health Organization (WHO) criteria. A 57-year-old man came to medical attention because of headaches. The patient medical history was otherwise unremarkable. Magnetic resonance imaging (MRI) revealed a 2.5 cm lesion, partially cystic, with an increased signal on T2-weighted imaging, located in the right frontal lobe. The patient underwent right frontal craniotomy and the surgical specimen was entirely evaluated. Microscopic examination showed a tumor arranged predominantly in sheets and nests, with an infiltrative growth pattern and oligodendroglioma-like appearance. Tumor cells were round to oval with cytoplasmic clearing, hyperchromatic nuclei and inconspicuous nucleoli. Only one mitosis was identified. Necrosis was absent. Differential diagnostic considerations included oligodendroglioma, clear cell ependymoma, polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and long-term epilepsy-associated tumor with clear cell morphology. Neoplastic cells showed positivity for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), α-thalasemia X-linked mental retardation syndrome (ATRX) (retained nuclear expression) and CD34. Epithelial membrane antigen (EMA), neuronal nuclear antigen, microtubule-associated protein-2e, cyclo-oxygenase-2, chromogranin A and isocitrate dehydrogenase 1 (IDH1) (R132H) were negative. Ki-67 labeling index was 2–3%. Molecular analysis identified neither IDH1/IDH2 mutations nor 1p19q codeletion. Rapidly accelerated fibrosarcoma homolog B1 (BRAF) V600E mutation was also absent by both molecular and immunohistochemical testing. Polymerase chain reaction analysis revealed the presence of fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil (TACC) fusion. Taken together, the morphological, immunohistochemical and molecular findings supported the final diagnosis of PLNTY.

AB - Low-grade neuroepithelial tumors (LGNT) show a broad histopathological spectrum and may be difficult to classify using current World Health Organization (WHO) criteria. A 57-year-old man came to medical attention because of headaches. The patient medical history was otherwise unremarkable. Magnetic resonance imaging (MRI) revealed a 2.5 cm lesion, partially cystic, with an increased signal on T2-weighted imaging, located in the right frontal lobe. The patient underwent right frontal craniotomy and the surgical specimen was entirely evaluated. Microscopic examination showed a tumor arranged predominantly in sheets and nests, with an infiltrative growth pattern and oligodendroglioma-like appearance. Tumor cells were round to oval with cytoplasmic clearing, hyperchromatic nuclei and inconspicuous nucleoli. Only one mitosis was identified. Necrosis was absent. Differential diagnostic considerations included oligodendroglioma, clear cell ependymoma, polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and long-term epilepsy-associated tumor with clear cell morphology. Neoplastic cells showed positivity for glial fibrillary acidic protein (GFAP), oligodendrocyte transcription factor 2 (OLIG2), α-thalasemia X-linked mental retardation syndrome (ATRX) (retained nuclear expression) and CD34. Epithelial membrane antigen (EMA), neuronal nuclear antigen, microtubule-associated protein-2e, cyclo-oxygenase-2, chromogranin A and isocitrate dehydrogenase 1 (IDH1) (R132H) were negative. Ki-67 labeling index was 2–3%. Molecular analysis identified neither IDH1/IDH2 mutations nor 1p19q codeletion. Rapidly accelerated fibrosarcoma homolog B1 (BRAF) V600E mutation was also absent by both molecular and immunohistochemical testing. Polymerase chain reaction analysis revealed the presence of fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil (TACC) fusion. Taken together, the morphological, immunohistochemical and molecular findings supported the final diagnosis of PLNTY.

KW - brain tumors

KW - CD34

KW - FGFR3-TACC3 fusion

KW - low-grade neuroepithelial tumor

KW - PLNTY

UR - http://www.scopus.com/inward/record.url?scp=85051049804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051049804&partnerID=8YFLogxK

U2 - 10.1111/neup.12504

DO - 10.1111/neup.12504

M3 - Article

VL - 38

SP - 557

EP - 560

JO - Neuropathology

JF - Neuropathology

SN - 0919-6544

IS - 5

ER -